Important Roles of GABA and Its Receptor Subtypes in Alzheimer’s Disease: A Mini Review
DOI:
https://doi.org/10.55006/biolsciences.2025.5404Keywords:
GABA, Alzheimer’s Disease, GABA receptor subtypes , Neurotransmitter, Cognitive processes , Neurodegeneration, Therapeutic targetsAbstract
This review is dedicated to a systematic evaluation of the involvement of Gamma-Aminobutyric Acid (GABA) and the three major receptor subtypes in the pathophysiology of Alzheimer’s disease. The core theme is how changes in GABAergic neurotransmission, receptor expression, synaptic inhibition, and network oscillatory dysfunction lead to cognitive decline, neurodegeneration, and disease progression. The review also outlines the therapeutic interventions designed to target the GABAergic signaling to lessen the Alzheimer's-related neuropathology. This review was conducted using a structured narrative approach to ensure a transparent and comprehensive synthesis of data on GABAergic mechanisms in Alzheimer’s disease. A systematic literature search was performed across PubMed, Scopus, Web of Science, and Google Scholar for studies published between 2000 and 2024. Search keywords included: “GABA AND Alzheimer’s disease,” “GABAergic dysfunction,” “GABA receptor subtypes,” “GABAA_AA receptors and AD,” “GABAB_BB signaling,” “GABAC_CC receptor function,” “inhibitory neurotransmission AND neurodegeneration.” GABA plays an important role in synchronization of neuronal transmission in brain and also functions for storing of memory. It performs physiological functions like production of controlling brain signals, interferon-γ production, and decrease the cell excitability. In this review article, we have shown the role of GABA and its types in Alzheimer’s disease AD.
Downloads
References
1. Abubakar M, Giri A, Goel F, Khan M, Gupta J, Kumar D, et al. Diabetes, Alzheimer’s disease risk factors, and the cafeteria diet: a comprehensive review. Curr Neuropharmacol. 2025;23(1):1–15.
2. Zhang W, Xiong BR, Zhang LQ, Huang X, Yuan X, Tian YK, et al. The role of the GABAergic system in diseases of the central nervous system. Neuroscience. 2021;470:88–99.
3. Goel F, Kumar D, Sharma A. Impact of corticoid receptors on Alzheimer’s disease: a neuroendocrine perspective. Inflammopharmacology. 2025;33(1):1–16.
4. Prévot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26(1):151–167.
5. Modgil S, Lahiri DK, Sharma VL, Anand A. Role of early life exposure and environment on neurodegeneration: implications on brain disorders. Transl Neurodegener. 2014;3(1):9.
6. Zhang W, Liu T, Li J, Singh J, Chan A, Islam A, et al. Decreased extrasynaptic δ-GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer’s disease. Br J Pharmacol. 2024;181(20):3944–3975.
7. Gonçalves Â. Altered neuronal activity in the hippocampal CA3 region in an in vitro model of tauopathy. Bordeaux: Université de Bordeaux; 2020.
8. Goel F, Singh P, Rai SN, Yadav DK. Nrf2/Keap1 signaling axis in the brain: master regulator of oxidative stress in neurodegenerative and psychiatric disorders. Mol Neurobiol. 2026;63(1):197–215.
9. Goel F, Giri A, Kumar D, Pal A, Singh P. Comparative information of different animal models used in chronic diseases. In: Advancements in Modeling-Based Therapeutics and Technology for Chronic Diseases. Elsevier; 2026. p. 51–84.
10. Goel F, Giri A, Khattri V, Singh P, Ata SMN. Mitochondrial dynamics and brain aging. In: Rejuvenating the Brain: Nutraceuticals, Autophagy, and Longevity. Springer; 2025. p. 95–116.
11. Andersen JV, Schousboe A. Metabolic dynamics of glutamate and GABA-mediated neurotransmission: the essential roles of astrocytes. J Neurochem. 2023;166(2):109–137.
12. Zerlaut Y, Tzilivaki A. Interneuronal modulations as a functional switch for cortical computations: mechanisms and implication for disease. Front Cell Neurosci. 2025;18:1479579.
13. Sharma P, Giri A, Goel F, Rai SN, Tripathi PN. Baicalein’s neuroprotective effects in a lansoprazole-induced Alzheimer’s model in Wistar rats. Eur J Clin Exp Med. 2025;23(1):1–10.
14. Ellis-Davies GC. Reverse engineering caged compounds: design principles for their application in biology. Angew Chem Int Ed. 2023;62(9):e202206083.
15. Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021;19(1):123–135.
16. Murala S, Yelam A, Ismail MM, Bollu PC. GABA. In: Neurochemistry in Clinical Practice. Springer; 2022. p. 73–89.
17. Chaudhary U. Neuromodulation in neural circuits: neurotransmitters and synaptic plasticity. In: Expanding Senses Using Neurotechnology. Springer; 2025. p. 225–245.
18. Tang X, Jaenisch R, Sur M. The role of GABAergic signalling in neurodevelopmental disorders. Nat Rev Neurosci. 2021;22(5):290–307.
19. Yeung JH, Walby JL, Palpagama TH, Turner C, Waldvogel HJ, Faull RL, et al. Glutamatergic receptor expression changes in the Alzheimer’s disease hippocampus and entorhinal cortex. Brain Pathol. 2021;31(6):e13005.
20. Poppi LA, Ho-Nguyen KT, Shi A, Daut CT, Tischfield MA. Recurrent implication of striatal cholinergic interneurons in neurodevelopmental,neurodegenerative, and neuropsychiatric disorders. Cells. 2021;10(4):907.
21. Melgosa-Ecenarro L, Doostdar N, Radulescu CI, Jackson JS, Barnes SJ. Pinpointing the locus of GABAergic vulnerability in Alzheimer’s disease. Semin Cell Dev Biol. 2023;139:35–54.
22. Andrew RD, Farkas E, Hartings JA, Brennan K, Herreras O, Müller M, et al. Questioning glutamate excitotoxicity in acute brain damage: the importance of spreading depolarization. Neurocrit Care. 2022;37(Suppl 1):11–30.
23. Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Exp Biol Med. 2021;246(9):1069–1083.
24. Cepeda C, Levine MS. Synaptic dysfunction in Huntington’s disease: lessons from genetic animal models. Neuroscientist. 2022;28(1):20–40.
25. Baracaldo-Santamaría D, Avendaño-Lopez SS, Ariza-Salamanca DF, Rodriguez-Giraldo M, Calderon-Ospina CA, González-Reyes RE, et al. Role of calcium modulation in the pathophysiology and treatment of Alzheimer’s disease. Int J Mol Sci. 2023;24(10):9067.
26. Alshial EE, Abdulghaney MI, Wadan AHS, Abdellatif MA, Ramadan NE, Suleiman AM, et al. Mitochondrial dysfunction and neurological disorders: a narrative review and treatment overview. Life Sci. 2023;322:122257.
27. Rao YL, Ganaraja B, Murlimanju B, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer’s disease. 3 Biotech. 2022;12(2):55.
28. Ghatak S, Talantova M, McKercher SR, Lipton SA. Novel therapeutic approach for excitatory/inhibitory imbalance in neurodevelopmental and neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2021;61:701–721.
29. Ren L. The mechanistic basis for the rapid antidepressant-like effects of ketamine. Prog Neuropsychopharmacol Biol Psychiatry. 2023;122:110910.
30. Wei TH, Hsieh CL. Effect of acupuncture on the p38 signaling pathway in nervous system diseases. Int J Mol Sci. 2020;21(13):4693.
31. Sakimoto Y, Oo PMT, Goshima M, Kanehisa I, Tsukada Y, Mitsushima D. Significance of GABAA receptor for cognitive function and hippocampal pathology. Int J Mol Sci. 2021;22(22):12456.
32. Ruffolo G, Gaeta A, Cannata B, Pinzaglia C, Aronica E, Morano A, et al. GABAergic neurotransmission in human tissues is modulated by cannabidiol. Life. 2022;12(12):2042.
33. Capsoni S, Arisi I, Malerba F, D’Onofrio M, Cattaneo A, Cherubini E. Targeting NKCC1 to re-establish GABAergic inhibition in Alzheimer’s disease. Brain Sci. 2022;12(6):783.
34. Petrache AL. Investigating cognitive performance and modulatory inhibitory interneurones in an Alzheimer’s disease mouse model. London: University College London; 2021.
35. Muñoz MD, de la Fuente N, Sánchez-Capelo A. TGF-β/Smad3 signalling modulates GABA neurotransmission. Int J Mol Sci. 2020;21(2):590.
36. Li Y, Zhu K, Li N, Wang X, Xiao X, Li L, et al. Reversible GABAergic dysfunction predicts early-stage Alzheimer disease. Alzheimers Res Ther. 2021;13(1):114.
37. Kang JQ. Epileptic mechanisms shared by Alzheimer’s disease. Int J Mol Sci. 2021;22(13):7133.
38. Chen L, Li X, Tjia M, Thapliyal S. Homeostatic plasticity and excitation-inhibition balance. Curr Opin Neurobiol. 2022;75:102553.
39. Jayathilake NJ, Phan TT, Kim J, Lee KP, Park JM. Modulating neuroplasticity for chronic pain relief. Exp Mol Med. 2025;57(1):1–14.
40. Tombini M, Boscarino M, Di Lazzaro V. Tackling seizures in patients with Alzheimer’s disease. Expert Rev Neurother. 2023;23(12):1131–1145.
41. Godoy LD, Prizon T, Rossignoli MT, Leite JP, Liberato JL. Parvalbumin role in epilepsy and psychiatric comorbidities. Front Integr Neurosci. 2022;16:765324.
42. Kumar D, Goel F, Singh P, Rai SN, Prasanth T. Understanding brain aging and cognitive decline. In: Rejuvenating the Brain. Springer; 2025. p. 1–23.
43. Pallanti S, Zohar J, Kasper S, Möller HJ, Hollander E. Revisiting benzodiazepines: a transdiagnostic approach. J Psychiatr Res. 2024;170:65–72.
44. Leuthold D, Herold NK, Nerlich J, Bartmann K, Scharkin I, Hallermann SJ, et al. Multi-behavioral phenotyping in zebrafish. bioRxiv. 2024:1–20.
45. Pinkiewicz M, Zaczyński A, Walecki J, Zawadzki M. Pharmacological strategies to enhance drug delivery across brain barriers. Int J Mol Sci. 2025;26(15):7050.
46. Bassetti D. Keeping the balance: GABAB receptors in the developing brain. Brain Sci. 2022;12(4):419.
47. Bi D, Wen L, Wu Z, Shen Y. GABAergic dysfunction drives Alzheimer’s disease pathogenesis. Alzheimers Dement. 2020;16(9):1312–1329.
48. Ochoa-de la Paz LD, Gulias-Cañizo R, Ruíz-Leyja ED, Sánchez-Castillo H, Parodí J. Role of GABA neurotransmitter in the human CNS. Rev Mex Neuroci. 2021;22(2):67–76.
49. Nimgampalle M, Chakravarthy H, Sharma S, Shree S, Bhat AR, Pradeepkiran JA, et al. Neurotransmitter systems in neurological disorders. Ageing Res Rev. 2023;88:101994.
50. Tadijan A, Vlašić I, Vlainić J, Đikić D, Oršolić N, Jazvinšćak Jembrek M. Cannabinoids in neurodegenerative conditions. Antioxidants. 2022;11(10):2049.
51. Sharma M, Pal P, Gupta SK. The neurotransmitter puzzle of Alzheimer’s disease. Brain Res. 2024;1810:148797.
52. Amani M, Mohammadian F, Golitabari N, Salari AA. Postnatal GABAA receptor activation alters cognition. Mol Neurobiol. 2022;59(6):3585–3599.
53. Xu Y, Zhao M, Han Y, Zhang H. GABAergic inhibitory interneuron deficits in Alzheimer’s disease. Front Neurosci. 2020;14:660.
54. Sciaccaluga M, Megaro A, Bellomo G, Ruffolo G, Romoli M, Palma E, et al. Unbalanced synaptic transmission and amyloid toxicity. Int J Mol Sci. 2021;22(11):5991.
55. Jeremic D, Sanchez-Rodriguez I, Jimenez-Diaz L, Navarro-Lopez JD. Therapeutic potential of GIRK channels. Pharmacol Ther. 2021;223:107808.
56. Carello-Collar G, Bellaver B, Ferreira PC, Ferrari-Souza JP, Ramos VG, Therriault J, et al. The GABAergic system in Alzheimer’s disease: a systematic review. Mol Psychiatry. 2023;28(1):1–12.
57. Ali AB, Islam A, Constanti A. Fate of interneurons and GABAA receptor subtypes in Alzheimer’s disease. Brain Pathol. 2023;33(1):e13129.
58. Ghit, A.; Assal, D.; Al-Shami, A. S.; Hussein, D. E. E., GABAA receptors: structure, function, pharmacology, and related disorders. Journal of Genetic Engineering and Biotechnology 2021, 19 (1), 1-15.
59. Sallard E, Letourneur D, Legendre P. Electrophysiology of ionotropic GABA receptors. Cell Mol Life Sci. 2021;78(13):5341–5370.
60. Michalettos G, Ruscher K. Crosstalk between GABAergic neurotransmission and inflammation. Front Cell Neurosci. 2022;16:807911.
61. Zheng Y, Bonfili L, Wei T, Eleuteri AM. Gut–brain axis in neurodegenerative disorders. Nutrients. 2023;15(21):4631.
62. Czapski GA, Strosznajder JB. Glutamate and GABA in microglia-neuron crosstalk in Alzheimer’s disease. Int J Mol Sci. 2021;22(21):11677.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sachchida Nand Rai, Prateek Gupta, Falguni Goel
This work is licensed under a Creative Commons Attribution 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
